Product Description
KBPA-101 is a human monoclonal antibody of the immunoglobulin M isotype, which is directed against the O-polysaccharide moiety of Pseudomonas aeruginosa serotype O11.
Mechanisms of Action: LPS Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kenta Biotech
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Pneumonia, Ventilator-Associated|Pneumonia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2007-000442-12 |
2007-000442-12 | P2 |
Completed |
Pneumonia |
2010-03-31 |
2022-03-12 |
Treatments |
|
NCT00851435 |
KB-101-002 | P2 |
Completed |
Pneumonia, Ventilator-Associated |
2009-07-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|